Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
Evogene and Unravel Biosciences have initiated a collaboration to develop a first-in-class therapy for demyelinating disorders, including Multiple Sclerosis.
Rezolute's Phase 3 sunRIZE study for congenital hyperinsulinism (HI) failed to meet primary or key secondary endpoints, despite demonstrating pharmacologic activity and reductions in hypoglycemia events.
Immunic completed enrollment in both Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis (RMS), expecting top-line data by end-2026.
